European Journal of Clinical Pharmacology

, Volume 33, Issue 5, pp 511–513

Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker

  • E. v. Möllendorff
  • K. Reiff
  • G. Neugebauer
Short Communications

DOI: 10.1007/BF00544245

Cite this article as:
v. Möllendorff, E., Reiff, K. & Neugebauer, G. Eur J Clin Pharmacol (1987) 33: 511. doi:10.1007/BF00544245

Summary

The pharmacokinetics and absolute bioavailability of carvedilol have been studied in 20 male healthy volunteers in a randomised 4-period, cross-over trial. Carvedilol 12,5 mg was given i.v., 50 mg was administered p.o. as a suspension and 25 and 50 mg were given in a capsule formulation. For the 50 mg capsule Cmax was 66 µg·l−1, tmax 1.2 h, t1/2 6.4 h. The t1/2 after i.v. administration was 2.4 h, CL 589 ml/min and Vz 132 l.

The absolute bioavailability was 24% (50 mg capsule). The kinetics after the 25 and 50 mg capsules were consistent with dose linearity.

Key words

carvedilol BM 14.190 pharmacokinetics bioavailability dose-linear kinetics 

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • E. v. Möllendorff
    • 1
  • K. Reiff
    • 1
  • G. Neugebauer
    • 1
  1. 1.Clinical PharmacologyBoehringer Mannheim GmbHMannheimFederal Republic of Germany

Personalised recommendations